Skip to Content

Novel Agent Increases PFS for Patients with endocrine-resistant HR+/HER2- metastatic breast cancer

New treatment option provides hope for patients with endocrine-resistant HR+/HER2- metastatic breast cancer, who until today have had very limited treatment options.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top